Veracyte, Inc.
VCYT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $132 | $130 | $114 | $119 |
| % Growth | 1.3% | 13.7% | -3.5% | – |
| Cost of Goods Sold | $43 | $40 | $35 | $40 |
| Gross Profit | $89 | $90 | $80 | $79 |
| % Margin | 67.8% | 69% | 69.5% | 66.4% |
| R&D Expenses | $16 | $16 | $18 | $19 |
| G&A Expenses | $0 | $14 | $52 | $47 |
| SG&A Expenses | $51 | $57 | $59 | $55 |
| Sales & Mktg Exp. | $0 | $43 | $7 | $8 |
| Other Operating Expenses | $0 | $22 | -$0 | $0 |
| Operating Expenses | $66 | $95 | $77 | $75 |
| Operating Income | $23 | -$5 | $3 | $4 |
| % Margin | 17.5% | -4% | 2.5% | 3.5% |
| Other Income/Exp. Net | -$4 | $7 | $5 | -$1 |
| Pre-Tax Income | $19 | $1 | $7 | $3 |
| Tax Expense | -$0 | $2 | $0 | -$2 |
| Net Income | $19 | -$1 | $7 | $5 |
| % Margin | 14.5% | -0.8% | 6.2% | 4.3% |
| EPS | 0.243 | -0.013 | 0.09 | 0.07 |
| % Growth | 2,044.8% | -113.9% | 28.6% | – |
| EPS Diluted | 0.24 | -0.013 | 0.088 | 0.06 |
| Weighted Avg Shares Out | 79 | 78 | 78 | 78 |
| Weighted Avg Shares Out Dil | 80 | 80 | 80 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $5 | $5 | $6 |
| EBITDA | $24 | $7 | $7 | $10 |
| % Margin | 18.3% | 5.2% | 5.7% | 8.2% |